Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin
- 12 December 2013
- journal article
- clinical trial
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 22 (5) , 1181-1187
Abstract
Women with ovarian carcinoma that are treated with paclitaxel/carboplatin are particularly susceptible to chemotherapy-induced nausea and vomiting (CINV). The current study evaluated the new combination (aprepitant/ramosetron/dexamethasone, 20 mg) in ovarian cancer patients receiving multiple cycles of paclitaxel/carboplatin.Keywords
This publication has 28 references indexed in Scilit:
- Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded studyKorean Journal of Anesthesiology, 2013
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based studySupportive Care in Cancer, 2011
- Efficacy according to Dexamethasone Dose in Combination with Aprepitant and Granisetron during Cisplatin-based ChemotherapyChonnam Medical Journal, 2010
- A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreSupportive Care in Cancer, 2007
- Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyCancer, 2005
- Incidence of chemotherapy‐induced nausea and emesis after modern antiemeticsCancer, 2004
- 5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and VomitingDrugs, 1998
- Ondansetron Compared with Metoclopramide in the Control of Emesis and Quality of Life during Repeated Chemotherapy for Breast CancerOncology, 1992
- Antiemetic Effects of YM060, a Potent and Selective Serotonin (5HT)3-Receptor Antagonist, in Ferrets and Dogs.The Japanese Journal of Pharmacology, 1991